Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision intervention study for osteoporotic fractures based on risk stratification
ChiCTR2300067942Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of calcium, vitamin d, alendronate, risedronate, denosumab and 1 more in osteoporosis, osteopenia and fragility fracture (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: New fragility fracture and Bone mineral density. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
calciumvitamin dalendronaterisedronatedenosumab
03
Conditions
osteoporosisosteopeniafragility fracture
Beyond the preview
Go deeper on ChiCTR2300067942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067942.